High expression of the eukaryotic initiation factors eIF4a and eIF4e in retinoblastoma.

IF 1.3 Q2 ONCOLOGY
Wspolczesna Onkologia-Contemporary Oncology Pub Date : 2025-01-01 Epub Date: 2025-09-17 DOI:10.5114/wo.2025.153882
Nora Fischer, Antje Schinlauer, Piotr Czapiewski, Yvonne Garbers, Christoph Garbers
{"title":"High expression of the eukaryotic initiation factors eIF4a and eIF4e in retinoblastoma.","authors":"Nora Fischer, Antje Schinlauer, Piotr Czapiewski, Yvonne Garbers, Christoph Garbers","doi":"10.5114/wo.2025.153882","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Retinoblastoma is a malignant, intraocular tumor which deve-lops within the first three years of life and has a variable prognosis. Aberrant expression of eukaryotic initiation factors (eIFs) has been reported in a variety of tumor entities, but there is a lack of data regarding eIF expression in retinoblastoma.</p><p><strong>Material and methods: </strong>We analyzed the expression of eIF4a and eIF4e in 30 retinoblastomas and samples of other ocular diseases via immunohisto-chemistry. Via western blot, we determined the expression of eIF4a and eIF4e in the two retinoblastoma cell lines WERI-Rb1 and Y79. Furthermore, we evaluated the influence of the eIF inhibitor 4EGI-1 on the cell viabi-lity of both cancer cell lines.</p><p><strong>Results: </strong>In this study, we observed increased expression of eIF4a and eIF4e in retinoblastoma samples compared to other ocular diseases. We also found that both proteins are expressed in the retinoblastoma cell lines WERI-Rb1 and Y79 and that their expression is independent of treatment with the eIF inhibitor 4EGI-1. However, inhibition of eIF function via 4EGI-1 reduced the cell viability of both cell lines in a dose- and time-dependent manner.</p><p><strong>Conclusion: </strong>We provide evidence that eIF4a and eIF4e are overexpressed in retinoblastoma and that their inhibition might represent a therapeutic target for the therapy of retinoblastoma.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"29 3","pages":"257-266"},"PeriodicalIF":1.3000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12518204/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Wspolczesna Onkologia-Contemporary Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/wo.2025.153882","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Retinoblastoma is a malignant, intraocular tumor which deve-lops within the first three years of life and has a variable prognosis. Aberrant expression of eukaryotic initiation factors (eIFs) has been reported in a variety of tumor entities, but there is a lack of data regarding eIF expression in retinoblastoma.

Material and methods: We analyzed the expression of eIF4a and eIF4e in 30 retinoblastomas and samples of other ocular diseases via immunohisto-chemistry. Via western blot, we determined the expression of eIF4a and eIF4e in the two retinoblastoma cell lines WERI-Rb1 and Y79. Furthermore, we evaluated the influence of the eIF inhibitor 4EGI-1 on the cell viabi-lity of both cancer cell lines.

Results: In this study, we observed increased expression of eIF4a and eIF4e in retinoblastoma samples compared to other ocular diseases. We also found that both proteins are expressed in the retinoblastoma cell lines WERI-Rb1 and Y79 and that their expression is independent of treatment with the eIF inhibitor 4EGI-1. However, inhibition of eIF function via 4EGI-1 reduced the cell viability of both cell lines in a dose- and time-dependent manner.

Conclusion: We provide evidence that eIF4a and eIF4e are overexpressed in retinoblastoma and that their inhibition might represent a therapeutic target for the therapy of retinoblastoma.

Abstract Image

Abstract Image

Abstract Image

真核起始因子eIF4a和eIF4e在视网膜母细胞瘤中的高表达。
视网膜母细胞瘤是一种恶性眼内肿瘤,发生于3岁以内,预后不一。真核起始因子(eIFs)的异常表达已在多种肿瘤实体中报道,但缺乏关于eIF在视网膜母细胞瘤中的表达的数据。材料与方法:采用免疫组化方法分析了eIF4a和eIF4e在30例视网膜母细胞瘤及其他眼部疾病标本中的表达。western blot检测了eIF4a和eIF4e在两种视网膜母细胞瘤细胞系WERI-Rb1和Y79中的表达。此外,我们评估了eIF抑制剂4EGI-1对两种癌细胞系细胞活力的影响。结果:在本研究中,我们观察到eIF4a和eIF4e在视网膜母细胞瘤样本中的表达高于其他眼部疾病。我们还发现这两种蛋白都在视网膜母细胞瘤细胞系WERI-Rb1和Y79中表达,并且它们的表达与eIF抑制剂4EGI-1的治疗无关。然而,通过4EGI-1抑制eIF功能以剂量和时间依赖的方式降低了两种细胞系的细胞活力。结论:我们提供了eIF4a和eIF4e在视网膜母细胞瘤中过表达的证据,抑制它们可能是治疗视网膜母细胞瘤的一个治疗靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.10
自引率
0.00%
发文量
22
审稿时长
4-8 weeks
期刊介绍: Contemporary Oncology is a journal aimed at oncologists, oncological surgeons, hematologists, radiologists, pathologists, radiotherapists, palliative care specialists, psychologists, nutritionists, and representatives of any other professions, whose interests are related to cancer. Manuscripts devoted to basic research in the field of oncology are also welcomed.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书